The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Chugai’s GYM329 may offset muscle loss linked to obesity drugs like orforglipron. Orforglipron’s success lifted Chugai’s stock, now ranked 11th by market cap in Tokyo. Ready to turn the ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

The weather is still holding up. Thank God for that. Very pleased to kick off our morning session this morning with Eli Lilly. We have Lucas Montarce, CFO; and Mike Czapar, Senior Vice President ...

Shares in Eli Lilly rose sharply in pre-market trading today after the company reported the first phase 3 results for orforglipron, a GLP-1 agonist that it hopes will offer an oral alternative to ...

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks.